Bristol Myers Squibb (NYSE:BMY) has reached an agreement to purchase Karuna Therapeutics (NASDAQ:KRTX), a company specializing in neuroscience drug development, for a total of $14 billion, as announced by both companies. As a result, Karuna shares jumped more than 46% intra-day today.

According to the acquisition terms, Bristol Myers Squibb will acquire Karuna at $330 per share in cash. This price includes the $1.3 billion in cash currently held by Karuna.

This acquisition, which is anticipated to be finalized in the first half of the next year, represents a strategic effort by Bristol Myers Squibb to enhance its portfolio in the psychiatric and neurological drugs sector.

Deja una respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

× ¿Cómo puedo ayudarte?